The original technology was developed by Yamaguchi University, Isao SAKIDA, and the technology will be provided to Kansas State University Medical School to supervise the trial. Liver cirrhosis (advanced decompensation) affects 20 million people worldwide and about 300 thousand people in Japan. In the SOP, a small amount (about 50 milliliters) of bone spinal fluid is collected from a patient under local anesthesia, cells containing bone marrow mesenchymal stem cells are cultured outside the body, and administered to the patient by drip infusion.
Shibuya Industry news release, January 6, 2017
Shibuya Industry applies for clincial trial in the USA of liver cirrhosis treatment using autologous bone marrow